Nano cap Diffusion Pharmaceuticals (NASDAQ:DFFN) is up 18% premarket on robust volume in reaction to its announcement that
the FDA will accelerate the review of its clinical development plan for
using lead drug trans sodium crocetinate (TSC) to treat COVID-19
patients with severe respiratory symptoms and low oxygen levels.
The company believes that small molecule TSC’s oxygen-enhancing mechanism of action could help these patients.
https://seekingalpha.com/news/3569084-diffusion-pharma-up-18-premarket-on-potential-use-of-tsc-in-covidminus-19
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.